Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7083655
Reference Type
Journal Article
Title
Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress
Author(s)
Mou, Z; Feng, Z; Xu, Z; Zhuang, Fei; Zheng, X; Li, X; Qian, J; Liang, G; ,
Year
2019
Is Peer Reviewed?
Yes
Journal
Biochemical and Biophysical Research Communications
ISSN:
0006-291X
EISSN:
1090-2104
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Location
SAN DIEGO
Volume
508
Issue
1
Page Numbers
243-249
Language
English
PMID
30477745
DOI
10.1016/j.bbrc.2018.11.128
Web of Science Id
WOS:000459089200036
Abstract
Diabetic nephropathy (DN) is a progressive kidney disease due to glomerular capillary damage in diabetic patients, with inflammation and oxidative stress implicated as crucial pathogenic factors. There is an urgent need to develop effective therapeutic drug. Natural medicines are rich resources for active lead compounds. They would provide new opportunities for the treatment of DN. The present study was designed to investigate the protective effects of Schisandrin B (SchB) on DN and to delineate the underlying mechanism. Oral administration of SchB in the diabetic mouse model significantly alleviated hyperglycemia-induced renal injury, which was accompanied by maintenance of urine creatinine and albumin levels at similar to those of control non-diabetic mice. Histological examination of renal tissue indicated that both development of fibrosis and renal cell apoptosis were dramatically inhibited by SchB. The protective effect of SchB on DN associated with suppression of inflammatory response and oxidative stress. These results strongly suggested that SchB could be a potential therapeutic agent for treatment of DN. Moreover, our findings provided a fuller understanding of the regulatory role of NF-kappa B and Nrf2 in DN, indicating that they could be important therapeutic targets. (C) 2018 Elsevier Inc. All rights reserved.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity